In: Phytochemistry Reviews, 2015, vol. 14, no. 2, p. 299-315
|
In: Science and Public Policy, 2018, vol. 45, no. 1, p. 92-102
|
(Working Papers SES ; 509)
Vaccine development is a lengthy, expensive and risky venture, with the research and development (R&D) process costing billions of dollars. The pre-clinical stage of vaccine R&D is largely performed by academic research institutions, then continued by the pharmaceutical industry though licensing agreements, taking the most promising candidates to the clinical testing stage. Governments play a...
|
In: Topoi, 2014, vol. 33, no. 2, p. 513-524
|
In: Communications, 2016, vol. 41, no. 3, p. 239-264
|
In: Topoi, 2014, vol. 33, no. 2, p. 459-475
|
In: Obesity Facts, 2019, vol. 12, no. 1, p. 40–66
The first contact for patients with obesity for any medical treatment or other issues is generally with General Practitioners (GPs). Therefore, given the complexity of the disease, continuing GPs’ education on obesity management is essential. This article aims to provide obesity management guidelines specifically tailored to GPs, favouring a practical patient-centred approach. The focus is...
|
In: Scientometrics, 2010, vol. 84, no. 2, p. 465-479
|
In: Swiss Journal of Geosciences, 2013, vol. 106, no. 3, p. 427-450
|
In: Pharmaceutical Research, 2005, vol. 22, no. 2, p. 173-174
|